#nivolumab

34 - Nivolumab in associazione a chemioterapia in prima linea per tumore dell’esofago a istologia squamosa
34 - Nivolumab in associazione a chemioterapia in prima linea per tumore dell’esofago a istologia squamosa
17 - Ipilimumab + nivolumab come trattamento di I linea nei pazienti con mesotelioma pleurico non resecabile a istologia non epitelioide
17 - Ipilimumab + nivolumab come trattamento di I linea nei pazienti con mesotelioma pleurico non resecabile a istologia non epitelioide
12 - Rimborsabilità di nivolumab+cabozantinib nel ca. del rene metastatico precedentemente non trattato (prima linea)
12 - Rimborsabilità di nivolumab+cabozantinib nel ca. del rene metastatico precedentemente non trattato (prima linea)
08 - Rimborsabilità di nivolumab + chemioterapia nel carcinoma gastroesofageo in prima linea
08 - Rimborsabilità di nivolumab + chemioterapia nel carcinoma gastroesofageo in prima linea
07 - Rimborsabilità di nivolumab + ipilimumab nel carcinoma del colon-retto MSI in seconda linea e oltre
07 - Rimborsabilità di nivolumab + ipilimumab nel carcinoma del colon-retto MSI in seconda linea e oltre
03 - Rimborsabilità di nivolumab+ipilimumab nel trattamento del melanoma, carcinoma renale e NSCLC
03 - Rimborsabilità di nivolumab+ipilimumab nel trattamento del melanoma, carcinoma renale e NSCLC
01 - Nuove opzioni terapeutiche per la pratica clinica nel GI
01 - Nuove opzioni terapeutiche per la pratica clinica nel GI
Cancro al seno HER2+/HER2-low metastatico, promettente la combo trastuzumab deruxtecan più nivolumab
Cancro al seno HER2+/HER2-low metastatico, promettente la combo trastuzumab deruxtecan più nivolumab
Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
Squamous Lung Cancer, Part 4: Immunotherapy (video)
Squamous Lung Cancer, Part 4: Immunotherapy (video)
Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials
Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials
Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
Immunotherapy for Lung Cancer: General Concepts
Immunotherapy for Lung Cancer: General Concepts
Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
What is Immunotherapy & Its Mechanisms of Action?
What is Immunotherapy & Its Mechanisms of Action?
Time to Response to Immunotherapy and the Concept of Pseudoprogression
Time to Response to Immunotherapy and the Concept of Pseudoprogression
The Current Role of Immunotherapy in the Treatment of Patients with Cancer
The Current Role of Immunotherapy in the Treatment of Patients with Cancer
Managing Immunotherapy Side Effects
Managing Immunotherapy Side Effects
What is the Optimal Duration of Immunotherapy?
What is the Optimal Duration of Immunotherapy?
Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?
Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?
Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
Immunotherapy for Lung Cancer
Immunotherapy for Lung Cancer
Immunotherapy for First Line Therapy of Advanced NSCLC
Immunotherapy for First Line Therapy of Advanced NSCLC
Data from Keynote 12 Nivolumab and Pembrolizumab
Data from Keynote 12 Nivolumab and Pembrolizumab
Immunotherapy for Small Cell Lung Cancer
Immunotherapy for Small Cell Lung Cancer
Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
Loading